CAMBRIDGE, Mass.--(BUSINESS WIRE)--FierceBiotech today named Foundation Medicine, Inc. as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.
“This company is fast. In just two years Foundation Medicine has developed a diagnostic test that helps investigators manage the fast-changing genetic information needed in clinical research and gives physicians a better tool to make some rational decisions on the drugs they choose to treat cancer victims,” says FierceBiotech Editor John Carroll. “It’s drawn the backing of some high-profile tech investors like Google Ventures. And, a lineup of cancer drug developers has signed on to work with the company on key cancer drug programs.”
“We are honored to be named to the 2012 Fierce 15 and believe this award is a testament to the progress Foundation Medicine continues to make toward our vision of transforming cancer care through the development of our fully informative genomic profile,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.
An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The 2012 Fierce 15 companies will be recognized today at the BioPharm America conference in Boston. A complete list of "Fierce 15" companies – the online newsletter's tenth annual selection – is available online at www.fiercebiotech.com.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical product, FoundationOneTM, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.foundationmedicine.com.
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark of Foundation Medicine, Inc.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.